Dashboard
Manage Tickers

CLLSCellectis S.A.

Nasdaq cellectis.com


$ 2.10 $ -0.08 (-3.69 %)    

Friday, 02-Aug-2024 13:40:11 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 447.95 $ -10.91 (-2.37 %)
DIA $ 397.31 $ -6.10 (-1.51 %)
SPY $ 532.92 $ -10.11 (-1.86 %)
TLT $ 98.17 $ 2.97 (3.12 %)
GLD $ 225.36 $ -0.43 (-0.19 %)
$ 2.09
$ 2.10
$ 2.14 x 200
$ 2.13 x 100
$ 2.10 - $ 2.10
$ 0.96 - $ 3.77
37,687
na
149.96M
$ 2.03
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

cellectis-announces-fda-grants-orphan-drug-designation-to-clls52-alemtuzumab-for-lymphodepletion-regimen-in-ucart22-evaluated-in-balli-01-clinical-trial-for-relapsedrefractory-b-cell-acute-lymphoblastic-leukemia
Cellectis Announces FDA Grants Orphan Drug...
08/01/2024 21:03:51

cellectis-announces-fda-grants-orphan-drug-and-rare-pediatric-disease-designation-to-ucart22-for-acute-lymphoblastic-leukemia-treatment-all-represents-10-of-us-leukemia-cases-and-progresses-rapidly
Cellectis Announces FDA Grants Orphan Drug...
07/25/2024 20:42:38

cellectis-publishes-scientific-article-demonstrating-three-key-factors-for-efficient-tale-base-editing
Cellectis Publishes Scientific Article Dem...
06/20/2024 20:31:49

cellectis-reports-publication-of-a-scientific-article-in-nature-communications-unveiling-non-viral-gene-therapy-approach-for-sickle-cell-disease
Cellectis Reports Publication Of A Scienti...
06/12/2024 20:38:08

oppenheimer-maintains-outperform-on-cellectis-lowers-price-target-to-10
Oppenheimer Maintains Outperform on Cellec...
06/12/2024 13:26:23

Oppenheimer analyst Hartaj Singh maintains Cellectis (NASDAQ:CLLS) with a Outperform and lowers the price target from $11 to...

cellectis-says-european-commission-has-granted-an-orphan-drug-designation-to-its-product-candidate-ucart22-for-treatment-of-acute-lymphoblastic-leukemia
Cellectis Says European Commission Has Gra...
06/04/2024 20:31:34

UCART22 is an allogeneic CAR T-cell product candidate targeting CD22 and evaluated in BALLI-01, a Phase 1/2 open-label dose-esc...

jmp-securities-reiterates-market-outperform-on-cellectis-maintains-6-price-target
JMP Securities Reiterates Market Outperfor...
05/31/2024 15:28:05

JMP Securities analyst Silvan Tuerkcan reiterates Cellectis (NASDAQ:CLLS) with a Market Outperform and maintains $6 price ta...

cellectis-q1-adj-014-beats-033-estimate-sales-650m-beat-370m-estimate
Cellectis Q1 Adj $(0.14) Beats $(0.33) Est...
05/28/2024 20:33:46

Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.33) by ...

12-health-care-stocks-moving-in-tuesdays-pre-market-session
12 Health Care Stocks Moving In Tuesday's ...
05/07/2024 12:06:20

Core News & Articles
Cellectis Announces Completion Of AstraZen...
05/06/2024 08:11:35

As part of the Additional Investment, AstraZeneca subscribed today for 10,000,000 "class A" convertible preferred share...

cellectis-appoints-arthur-stril-as-interim-chief-financial-officer-replacing-mr-bing-wang
Cellectis Appoints Arthur Stril As Interim...
05/02/2024 21:35:55

Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platf...

cellectis-q4-2023-gaap-eps-064-misses-026-estimate-sales-1990m-miss-16263m-estimate
Cellectis Q4 2023 GAAP EPS $(0.64) Misses ...
04/29/2024 20:49:30

Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.64) per share which missed the analyst consensus estimate of $(0.26) b...

cellectis-to-present-data-on-talen-editing-process-at-asgct-mat-7-11
Cellectis To Present Data On TALEN Editing...
04/22/2024 20:38:50

cellectis-publishes-novel-intronic-gene-editing-approach-for-inborn-metabolic-diseases-by-edited-hspcs
Cellectis Publishes Novel Intronic Gene Ed...
04/10/2024 20:31:47

c

cellectis-announces-two-poster-presentations-on-novel-talen-editing-process-for-gene-correction-and-gene-insertion-in-hspcs-at-the-asgct-annual-meeting
Cellectis Announces Two Poster Presentatio...
04/08/2024 20:36:46

Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platf...

Core News & Articles
Cellectis Announces The Execution Of The S...
11/15/2023 08:26:20

cellectis-q3-2023-adj-eps-036-beats-042-estimate-sales-164m-miss-358m-estimate
Cellectis Q3 2023 Adj EPS $(0.36) Beats $(...
11/06/2023 22:03:20

Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.42) by ...

earnings-scheduled-for-november-6-2023
Earnings Scheduled For November 6, 2023
11/06/2023 13:24:53

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on ...

earnings-preview-cellectis
Earnings Preview: Cellectis
11/03/2023 19:01:17

cellectis-to-present-preliminary-results-of-nathali01-and-updated-results-of-the-balli01-phases-i-trials-at-the-american-society-of-hematology--65th-annual-meeting
Cellectis To Present Preliminary Results O...
11/02/2023 21:42:37

 Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing plat...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

08/02/2024 Humana Inc. (HUM)
08/05/2024 Marinus Pharmaceuticals, Inc. (MRNS)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)